Ireland· IE-PA-EU/1/20/1433/001-004
Fluad Tetra suspension for injection in pre-filled syringe
A influenza, inaktiviert, spalt/split virus oder oberflächen-antigen product containing a/(h1n1)-like virus antigen + a/(h3n2)-like vurus antigen + b (victoria lineage) - like virus antigen + b (yamagata lineage)-like virus antigen, registered in Ireland by Seqirus Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen is registered in 11 of 19 countries.
Countries holding a registration under ATC J07BB02 (influenza, inaktiviert, spalt/split virus oder oberflächen-antigen), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen · ATC J07BB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- A/(H1N1)-LIKE VIRUS ANTIGEN + A/(H3N2)-LIKE VURUS ANTIGEN + B (Victoria Lineage) - Like Virus Antigen + B (Yamagata Lineage)-Like Virus Antigen
- Manufacturer
- Seqirus Netherlands B.V.
- Country
- Ireland (IE)
- ATC code
- J07BB02
- ATC class
- Influenza, inaktiviert, Spalt/Split Virus oder Oberflächen-Antigen
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- June 8, 2026
Packs & prices · 1
- ie_pa_numberEU/1/20/1433/001-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BB02
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen, as other registers publish it.
- PolandAdjupanrixGlaxoSmithKline Biologicals S.A.
- DenmarkAdjupanrixGlaxoSmithKline Biologicals S.A.
- BelgiumAdjupanrixGlaxoSmithKline Biologicals
- IcelandAdjupanrixGlaxoSmithKline Biologicals S.A.*
- FinlandAdjupanrixGlaxoSmithKline Biologicals SA
- CzechiaADJUPANRIXGlaxoSmithKline Biologicals S.A., Rixensart
- IrelandAdjupanrix suspension and emulsion for emulsion for injection. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)GlaxoSmithKline Biologicals S.A.
- NetherlandsAdjupanrix, (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals, suspensie en emulsie voor emulsie voor injectieGlaxoSmithKline Biologicals S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8f92f84-b585-4560-b52a-976e865f59da GET /v1/drugs/b8f92f84-b585-4560-b52a-976e865f59da?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Suspension for injection in pre-filled syringe",
"routes": [
"Intramuscular use"
],
"source": "hpra",
"atc_all": [
"J07BB02"
],
"strength": null,
"pa_number": "EU/1/20/1433/001-004",
"substances": [
"A/(H1N1)-LIKE VIRUS ANTIGEN",
"A/(H3N2)-LIKE VURUS ANTIGEN",
"B (Victoria Lineage) - Like Virus Antigen",
"B (Yamagata Lineage)-Like Virus Antigen"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "20/05/2020",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about influenza, inaktiviert, spalt/split virus oder oberflächen-antigen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.